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down  the  spread of  SARS-CoV-2,  there  are  no  signs  that  these measures will  completely  stop  the 





vaccine  should  induce humoral  immunity  through neutralizing antibodies.  In addition,  induction of 
cellular immunity by such vaccines might increase its efficacy [2–4]. Although some SARS-CoV-1 and MERS 
clinical trials have resulted in the induction of promising immune responses, these have been small, 
and no efficacy  trial has been conducted  to date  for any human coronavirus  vaccine.  [5,6] Given  the 
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urgent need for a vaccine against COVID-19, so far over 200 vaccine candidates are under development 
and in different stages of (pre)clinical testing. In this report, we aim at giving an overview of the general 
approaches  and  challenges  regarding  the  current  COVID-19  vaccine  development  endeavors  and 
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system and by  skewing  adaptive  immune  responses  and  are  usually  essential  vaccine  components. 











kilobases)  encodes  a  nonstructural  replicase  polyprotein  and  structural  proteins,  including  spike, 
envelope, membrane  and nucleocapsid  proteins  (Figure 2).  The  spike  glycoprotein  (SP)  is  naturally 
presented  as  a  heavily  glycosylated  trimer  and  is  required  for  both  target  cell  binding  and  viral 










delivery of  the  vaccine,  instead of parenteral  injection,  is being considered  to elicit  robust mucosal 
immune  responses.  However,  the  physicochemical  barriers  created  by  mucosal  surfaces  are  a 










Nucleic  acid  (DNA  and  RNA)  based  vaccines  carry  a  nucleotide  sequence  encoding  the  protein  of 
interest.  This  approach  uses  the  host  cellular machinery  to  generate  foreign  antigens  that  can  be 
presented in the context both major histocompatibility complex (MHC) class I and class II molecules of 
antigen-presenting  cells  (APCs),  thereby  eliciting  both  humoral  and  cellular  immune  responses. 
Interestingly, although there is currently no nucleic acid-based vaccine available on the market, nucleic 
acid vaccines do show great promise in the COVID-19 vaccine race. Firstly, they have the potential for 
rapid,  inexpensive and  scalable manufacture, which  is  essential  in  setting of a pandemic outbreak. 
Secondly, nucleic acids instruct host cells to synthesize SP without the struggling with protein folding, 
purification,  solubility  and  inappropriate  glycosylation  issues  that  are  commonly  associated  with 
recombinant  protein  synthesis,  thereby  matching  better  with  virus’  own  glycoprotein  coat.[17,18] 
Importantly, DNA/RNA  requires  a  delivery  system  to  reach  its  target  (i.e.  cell  nucleus  for DNA and 
cytoplasm for RNA). In the context of nucleic acid based COVID-19 vaccine development, liposomes 
and lipid nanoparticles (LNP), together with electrophysiological methods such as electroporation are 






hold  several  attractive  advantages.  For  example,  mRNA  triggers  rapid  and  immediate  antigen 
expression in the cytoplasm without the need for crossing the nuclear membrane. In addition, there is 






derived,  self-amplifying  RNA  (saRNA).  Conventional  mRNA-based  vaccine  encodes  the  antigen  of 
 - 5 - 
interest,  whereas  saRNA  also  encodes  a  viral  replication machinery  that  enables  intracellular  RNA 





and  Moderna  to  be  evaluated  in  a  clinical  trial  (NCT04283461)  fueled  by  their  prior  efforts  on 
coronavirus  vaccine  development.  After  the  genetic  information  of  SARS-CoV-2  recently  became 
available, mRNA encoding SP of the virus was synthesized and formulated into LNP using their existing 
mRNA delivery  system.  The  latter  is  composed  of  a  proprietary  ionizable  lipid  (SM-102)  and  three 
commercially available lipids.[27,28] Accomplishing a phase I trial with promising outcome (not published 
yet), Moderna has started clinical trial  II  (NCT04405076) with amended dose  levels. Meanwhile the 
phase III study protocol is finished and the study is expected to be launched in July 2020.[29] 
BioNTech and Pfizer are jointly developing BNT162 as a SARS-CoV-2 mRNA vaccine into clinical trial on 











The  CureVac  mRNA  vaccine  candidate  utilizes  nucleotides  without  chemical  modifications  in  the 
mRNA, encodes the full-length SP and is formulated as LNP. This vaccine has been evaluated in various 







with  the  LUNAR®  (lipid-enabled  and  unlocked  nucleic  acid  modified  RNA),  an  ionizable  and 
biodegradable  LNP platform.[33]  They expect  their  vaccine  to elicit  an  immune  response using much 






nuclear  membrane  to  become  translated,  which  is  a  major  barrier  for  DNA-based  therapeutics. 




by  their  experience  gathered  from  INO-4700,  a MERS-CoV  vaccine which was  shown  to  be well-
tolerated  and  capable  to  induce  strong  antibody  and  T  cell  responses.[6]  INO-4800  is  composed  of 
optimized DNA plasmids that are designed to express the SP of SARS-CoV-2. Moreover, to improve the 
































infection  and  induce  potent  immune  responses,  often  without  the  need  for  additional  adjuvants. 
However,  viral  vectors  are  genetically modified  organisms  (GMOs)  and  are  therefore  treated with 
caution. 












which ChAdOx1 MERS was  safe  and well  tolerated, whereas  a  single dose was  able  to  elicit  both 
humoral and cellular  responses against MERS-CoV.[46] The phase  I  trial  (NCT04324606) of ChAdOx1 
COVID-19,  involving  over  1000  participants,  is  currently  completed,  and  a  phase  II/III  trial 




























a  fast  path  for  developing  a  COVID-19  vaccine.  Sanofi  Pasteur  uses  its  recombinant  DNA  in  vitro 
platform  that produces an exact genetic match  to SP. The DNA sequence will be  combined  into a 
baculovirus expression platform, the basis of Sanofi’s licensed recombinant influenza vaccine, which 
allows  for  rapid production of  large quantities of antigen.[54] Sanofi Pasteur plans  to  initiate phase  I 
clinical trials in the second half of 2020.[55] 
A team from the University of Queensland announced a subunit vaccine candidate for which they used 
a  technique  called a  ‘molecular  clamp’.  It's  a novel  thermally-stable  trimerisation domain,  that  can 
constrain  a  recombinant  protein  (i.e.  SP  of  SARS-CoV-2)  to  its  prefusion,  trimeric  conformation, 
expecting  to  expose  the  conserved  stem  domain  to  the  immune  system,  while  simultaneously 
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Novavax, a late-stage biotech company, has developed a SARS-CoV-2 subunit vaccine (NVX-CoV2373) 









The majority of  the  currently  available human vaccines  are based on  inactivated or  live  attenuated 
viruses. Live attenuated vaccines, engineered from much less virulent version of the pathogen, are often 







durable protection.[49] Additionally,  the efficacy of  inactivated virus  vaccine can be dampened when 
crucial viral neutralizing epitopes are destroyed during the inactivation process. 
Codagenix and the Serum Institute of India are co-developing a live-attenuated vaccine against SARS-
CoV-2.  Codagenix  uses  viral  deoptimization  to  synthesize  a  "rationally  designed,"  live-attenuated 
vaccine, starting from the digital sequence of the viral genome. This viral vaccine still requires animal 
testing prior to initiating clinical trials.[62] 
Dynavax  Technologies  is  collaborating  with  Sinovac  Biotech  to  develop  an  inactivated  COVID-19 
vaccine  in combination with the FDA approved adjuvant CpG 1018 (NCT04352608). The  latter  is a 
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CoV-2,  induced  by  natural  infection  or  vaccination.  This  to  optimize  protection  and  to  avoid  that 




Another  possible  complication  is  whether  SARS-CoV-2  can  change  antigenically  through  genetic 
mutations and thereby avoid immunity.[71] At present it is not yet known whether SARS-CoV-2 mutations 



































































 RBD  Academy of Military Sciences/ 
Walvax Biotech 
Pre-clinical Naked mRNA SP  China CDC/Tongji University[76] 






































Plasmid DNA  ID Zydus Cadila 









Pre-clinical Plasmid DNA SP  Zydus Cadila[80] 
Pre-clinical Delivered by 
bacteriophage 





























  GeoVax/BravoVax[82] 
Pre-clinical Ad vector SP IN Altimmune[83] 
Pre-clinical Ad vector   Greffex[84] 




SP IN University of Hong Kong[87] 













































  IM Anhui Zhifei Longcom 
Biologic Pharmacy Co., Ltd. 
Pre-clinical  RBD  Vaxil Bio[94] 
Pre-clinical  SP  AJ Vaccines[95] 
Pre-clinical Activated by T-Cell 
called li-Key 
RBD  Generex/EpiVax[96] 




SP IM Sanofi Pasteur/GSK[55] 



























Pre-clinical Adjuvant:AS03 truncated SP  Innovax/Xiamen Univ./GSK[105] 
Pre-clinical  SP  WRAIR/USAMRIID[106] 














SP IM ExpreS2ion/ AdaptVac[107,108] 
Pre-clinical Plant derived 
VLP 
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